Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 08 Nov 2014
At a glance
- Drugs Dasatinib (Primary) ; Ixabepilone (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2012 Planned end date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 26 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.